Novo reports first Ozempic sales drop in greater China region

Core Insights - Sales of Novo Nordisk's diabetes drug Ozempic in the greater China region experienced a decline for the first time last year due to increased competition from rival products [1] Company Summary - Novo Nordisk's flagship product, Ozempic, has faced challenges in maintaining its market position in the greater China region [1] - The decline in sales indicates a shift in the competitive landscape for diabetes medications in this market [1] Industry Summary - The diabetes drug market in greater China is becoming increasingly competitive, impacting sales of established products like Ozempic [1] - Rival companies are likely introducing new products or strategies that are affecting Novo Nordisk's market share [1]